MML Investors Services LLC purchased a new position in shares of West Pharmaceutical Services Inc. (NYSE:WST) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,012 shares of the medical instruments supplier’s stock, valued at approximately $372,000.

Several other hedge funds have also recently added to or reduced their stakes in WST. Meeder Asset Management Inc. bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at about $101,000. Pendal Group Ltd bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at about $181,000. Integrated Investment Consultants LLC bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $155,000. Bradley Foster & Sargent Inc. CT bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at about $210,000. Finally, Penobscot Investment Management Company Inc. bought a new stake in West Pharmaceutical Services during the 3rd quarter valued at about $217,000. 92.50% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, August 10th. ValuEngine upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Wednesday, October 17th.

Shares of WST opened at $106.02 on Friday. West Pharmaceutical Services Inc. has a 1-year low of $82.74 and a 1-year high of $125.09. The stock has a market cap of $8.09 billion, a P/E ratio of 38.14, a P/E/G ratio of 4.09 and a beta of 1.19. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.94 and a quick ratio of 2.23.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.70 by $0.06. West Pharmaceutical Services had a net margin of 9.06% and a return on equity of 15.78%. The company had revenue of $431.70 million during the quarter, compared to analyst estimates of $427.55 million. Research analysts forecast that West Pharmaceutical Services Inc. will post 2.83 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “MML Investors Services LLC Purchases New Position in West Pharmaceutical Services Inc. (WST)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/12/08/mml-investors-services-llc-purchases-new-position-in-west-pharmaceutical-services-inc-wst.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: Book Value Per Share in Stock Trading

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.